PLx Pharma Inc. (PLXP) Research

PLx Pharma Inc. is a U.S.-based entity leveraging its innovative drug delivery platform technology, having successfully transitioned into the commercial stage. The company's primary offerings include Vazalore 325 mg, which is formulated for individuals facing vascular incidents like heart attacks and clot-induced strokes, as well as for the management of pain and inflammation. Additionally, they provide Vazalore 81 mg in the form of liquid-filled aspirin capsules. Looking ahead, their product development pipeline features PL1200 Ibuprofen 200 mg and PL1100 Ibuprofen 400 mg, both of which are in Phase I clinical trials for addressing pain, inflammation, and fever. PLx Pharma makes its products available to consumers through a variety of retail avenues, including pharmacies, major retailers, supermarkets, and online sales channels. Founded in 2002, PLx Pharma Inc. is headquartered in Sparta, New Jersey.

Market snapshot

Symbol
PLXP
Price
$0.09
Day change
0.00%
Market cap
$2.5M
P/E ratio
-0.04x
52-week range
0.009-3.41
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic

Peer companies

  • Applied DNA Sciences, Inc. (APDN)
  • Athenex, Inc. (ATNX)
  • Aspira Women's Health Inc. (AWH)
  • Biophytis S.A. (BPTS)
  • Eiger BioPharmaceuticals, Inc. (EIGRQ)
  • Vyome Holdings, Inc. (HIND)
  • Novan, Inc. (NOVN)
  • Notable Labs, Ltd. (NTBL)

Recent insider activity

  • Giordano Natasha — P-Purchase (4100 shares) on 2022-03-15
  • O'Connor Rita M — P-Purchase (3700 shares) on 2022-03-15
  • O'Connor Rita M — P-Purchase (10000 shares) on 2022-03-15
  • Valentino Michael J — A-Award (80000 shares) on 2022-02-22
  • O'Connor Rita M — A-Award (110000 shares) on 2022-02-22

Open PLx Pharma Inc. (PLXP) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.